Literature DB >> 27318832

Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample.

Chobufo Ditah1, James Otvos2, Hisham Nassar3, Dorith Shaham4, Ronit Sinnreich5, Jeremy D Kark6.   

Abstract

BACKGROUND AND AIMS: Failure of trials to observe benefits by elevating plasma high-density lipoprotein cholesterol (HDL-C) has raised serious doubts about HDL-C's atheroprotective properties. We aimed to identify protective HDL biomarkers by examining the association of nuclear magnetic resonance (NMR) measures of total HDL-particle (HDL-P), large HDL-particle, and small and medium-sized HDL-particle (MS-HDL-P) concentrations and average HDL-particle size with coronary artery calcification (CAC), which reflects the burden of coronary atherosclerosis, and compare with that of HDL-C.
METHODS: Using a cross-sectional design, 504 Jerusalem residents (274 Arabs and 230 Jews), recruited by population-based probability sampling, had HDL measured by NMR spectroscopy. CAC was determined by multidetector helical CT-scanning using Agatston scoring. Independent associations between the NMR measures and CAC (comparing scores ≥100 vs. <100) were assessed with multivariable binary logistic models.
RESULTS: Comparing tertile 3 vs. tertile 1, we observed protective associations of HDL-P (multivariable-adjusted OR 0.42, 95% CI 0.22-0.79, plinear trend = 0.002) and MS-HDL-P (OR 0.36, 95% CI 0.19-0.69), plinear trend = 0.006 with CAC, which persisted after further adjustment for HDL-C. HDL-C was not significantly associated with CAC (multivariable-adjusted OR 0.59, 95% CI 0.27-1.29 for tertiles 3 vs. 1, plinear trend = 0.49). Large HDL-P and average particle size (which are highly correlated; r = 0.83) were not associated with CAC: large HDL-P (OR 0.77, 95% CI 0.33-1.83, plinear trend = 0.29) and average HDL-P size (OR 0.72, 95% CI 0.35-1.48, plinear trend = 0.58).
CONCLUSIONS: MS-HDL-P represents a protective subpopulation of HDL particles. HDL-P and MS-HDL-P were more strongly associated with CAC than HDL-C. Based on the accumulating evidence, incorporation of MS-HDL-P or HDL-P into the routine prediction of CHD risk should be evaluated.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Arabs; Coronary calcification; HDL cholesterol; HDL particles; Jews; Large HDL particles; Medium-sized HDL particles; Small HDL particles

Mesh:

Substances:

Year:  2016        PMID: 27318832     DOI: 10.1016/j.atherosclerosis.2016.06.010

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  Refocusing the AIM on HDL in the metabolic syndrome.

Authors:  Robert W McGarrah
Journal:  Atherosclerosis       Date:  2016-07-02       Impact factor: 5.162

2.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

3.  High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Authors:  Tomas Vaisar; Jenny E Kanter; Jake Wimberger; Angela D Irwin; John Gauthier; Emily Wolfson; Vanessa Bahnam; I-Hsien Wu; Hetal Shah; Hillary A Keenan; Carla J Greenbaum; George L King; Jay W Heinecke; Karin E Bornfeldt
Journal:  Diabetes Care       Date:  2019-10-09       Impact factor: 19.112

4.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Structure-function relationships of HDL in diabetes and coronary heart disease.

Authors:  Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein
Journal:  JCI Insight       Date:  2020-01-16

6.  Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study.

Authors:  Annelise Genoux; Laeticia Lichtenstein; Jean Ferrières; Thibaut Duparc; Vanina Bongard; Paul-Louis Vervueren; Guillaume Combes; Dorota Taraszkiewicz; Meyer Elbaz; Michel Galinier; Bertrand Nassar; Jean-Bernard Ruidavets; Bertrand Perret; Laurent O Martinez
Journal:  BMC Med       Date:  2016-08-23       Impact factor: 8.775

7.  High-density lipoprotein 3 cholesterol is a predictive factor for arterial stiffness: a community-based 4.8-year prospective study.

Authors:  Fan Wang; Xiaona Wang; Ping Ye; Ruihua Cao; Yun Zhang; Yue Qi; Dong Zhao
Journal:  Lipids Health Dis       Date:  2018-01-05       Impact factor: 3.876

Review 8.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

9.  Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study.

Authors:  Bertrand Perret; Laurent O Martinez; Thibaut Duparc; Jean-Bernard Ruidavets; Annelise Genoux; Cécile Ingueneau; Souad Najib; Jean Ferrières
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

10.  APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.

Authors:  Jung-Hwa Ryu; Mengyuan Ge; Sandra Merscher; Avi Z Rosenberg; Marco Desante; Hila Roshanravan; Koji Okamoto; Myung K Shin; Maarten Hoek; Alessia Fornoni; Jeffrey B Kopp
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.